Who owns Summit Therapeutics Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SMMT from SEC Form 13F filings across 296 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 296 institutions disclosed 134.7M shares of Summit Therapeutics Inc. worth $2.28B — about 16.9% of shares outstanding; the largest disclosed holder is BAKER BROS. ADVISORS LP. Source: SEC Form 13F filings, parsed by EvidInvest.
296
13F holders
$2.28B
value, 2026 filers
16.9%
of shares outstanding (134.7M sh)
94
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of SMMT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 32.8M | $554.4M | 2.6% | 4.1% | 0.0% |
| 2 | BlackRock, Inc. | 10.4M | $175.3M | 0.0% | 1.3% | +8.8% |
| 3 | FMR LLC | 8.1M | $137.6M | 0.0% | 1% | -19.0% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 7.2M | $122.3M | 0.0% | 0.9% | +26.1% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.7M | $113.6M | 0.0% | 0.8% | +33.2% |
| 6 | STATE STREET CORP | 6.1M | $103.0M | 0.0% | 0.8% | -36.1% |
| 7 | PRICE T ROWE ASSOCIATES INC /MD/ | 5.3M | $89.6M | 0.0% | 0.7% | +36.0% |
| 8 | CITADEL ADVISORS LLC | 3.8M | $64.0M | 0.0% | 0.5% | +119.2% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 3.5M | $59.0M | 0.0% | 0.4% | +1.8% |
| 10 | Kynam Capital Management, LP | 3.0M | $50.7M | 2.8% | 0.4% | +150.0% |
| 11 | UBS Group AG | 3.0M | $50.1M | 0.0% | 0.4% | -43.4% |
| 12 | TWO SIGMA INVESTMENTS, LP | 2.3M | $38.2M | 0.0% | 0.3% | +224.4% |
| 13 | Bellevue Group AG | 2.1M | $35.7M | 0.7% | 0.3% | +13733.9% |
| 14 | D. E. Shaw & Co., Inc. | 2.1M | $35.5M | 0.0% | 0.3% | +69.0% |
| 15 | AQR CAPITAL MANAGEMENT LLC | 2.0M | $33.1M | 0.0% | 0.2% | +263.2% |
| 16 | Aberdeen Group plc | 1.7M | $29.4M | 0.0% | 0.2% | +2.7% |
| 17 | Candriam S.C.A. | 1.7M | $28.2M | 0.1% | 0.2% | +212.3% |
| 18 | MORGAN STANLEY | 1.2M | $20.5M | 0.0% | 0.2% | -16.3% |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.2M | $20.0M | 0.0% | 0.1% | +127.2% |
| 20 | BANK OF AMERICA CORP /DE/ | 1.2M | $19.6M | 0.0% | 0.1% | +34.0% |
| 21 | Pictet Asset Management Holding SA | 1.1M | $18.8M | 0.0% | 0.1% | -1.2% |
| 22 | Opaleye Management Inc.NEW | 1.1M | $17.8M | 2.0% | 0.1% | new |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.0M | $17.7M | 0.0% | 0.1% | +7.3% |
| 24 | VANGUARD FIDUCIARY TRUST CO | 1.0M | $17.4M | 0.0% | 0.1% | +6.4% |
| 25 | Trexquant Investment LP | 937,011 | $15.8M | 0.1% | 0.1% | +409.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.